Skip to content

A Clinical Trial to Prevent the Complications of Insulin Resistance (Including Type-2 Diabetes)

A Clinical Trial to Prevent the Complications of Insulin Resistance (Including Type-2 Diabetes)

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00015626
Enrollment
300
Registered
2001-04-26
Start date
Unknown
Completion date
Unknown
Last updated
2005-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus, Insulin Resistance

Brief summary

The goal of this study is to aggressively treat insulin resistance and its clinical manifestations when they first appear in childhood, and to prevent the subsequent progression towards impaired glucose tolerance and type-2 diabetes. In the process of this clinical trial, we will learn more about the early manifestations of insulin resistance, its treatment, and its relationship to obesity and type-2 diabetes through parallel in-vivo and in-vitro studies.

Interventions

DRUGrosiglitazone
DRUGMetformin
PROCEDUREskin biopsy
BEHAVIORALdiet and exercise
DRUGpioglitazone

Sponsors

National Center for Research Resources (NCRR)
Lead SponsorNIH

Study design

Allocation
RANDOMIZED
Primary purpose
TREATMENT
Masking
DOUBLE

Eligibility

Sex/Gender
ALL
Age
5 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Obese patients (wt \> 95th percentile for age, for adults increased BMI \> 27) greater than 5 years of age 2. And/or presence of complications of insulin resistance such as acanthosis nigricans, dyslipidemia, elevated blood pressure, hyperandrogenism 3. Siblings and parents of patients with insulin resistance. Siblings and parents will be included only in the case of documented insulin resistance in the index subject. Insulin resistance will be documented by OGTT and/or IVGTT. 4. Family history of type II diabetes.

Exclusion criteria

1. Critically ill patients, patients will congestive heart failure, renal or liver insufficiency 2. Inability to give consent. 3. History of poor compliance with physician's recommendations

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026